In adults with obesity and type 2 diabetes, receiving bimagrumab via intravenous injection once a week for 48 weeks reduces body fat by 22.2% and increases lean mass by 3.6%, without changes in calorie intake, showing the drug directly alters body composition.
See the scientific wording
In adults with obesity and type 2 diabetes, weekly intravenous administration of bimagrumab at 10 mg/kg for 48 weeks reduces total body fat mass by approximately 22.2% and increases total body lean mass by 3.6%, despite no significant change in daily caloric intake, indicating a direct pharmacological effect on body composition independent of appetite suppression.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman
This drug, bimagrumab, helped people with obesity and diabetes lose fat and gain muscle without making them eat less — meaning it directly changed how their bodies stored fat and built muscle, like a targeted reset button for body composition.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Bimagrumab binds to specific receptors on muscle and fat cells, blocking signals that normally limit muscle growth and promote fat storage. This allows muscle cells to build more protein and grow larger, while fat cells stop storing fat and break down existing fat deposits, leading to more muscle and less fat without changing food intake.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with obesity and type 2 diabetes, receiving bimagrumab via intravenous injection once a week for 48 weeks reduces body fat by 22.2% and increases lean mass by 3.6%, without changes in calorie intake, showing the drug directly alters body composition.
Mechanism
1 studyBimagrumab blocks signals that normally stop muscles from growing and fat cells from burning fat. This lets muscles get bigger and fat stores shrink, even when food intake stays the same.
Bimagrumab binds to specific receptors on muscle and fat cells, blocking signals that normally limit muscle growth and promote fat storage. This allows muscle cells to build more protein and grow larger, while fat cells stop storing fat and break down existing fat deposits, leading to more muscle and less fat without changing food intake.
Bimagrumab binds with high affinity to ActRIIA and ActRIIB receptors on the surface of skeletal muscle and adipose tissue cells
Binding of bimagrumab prevents activin ligands, including myostatin and activin A, from engaging ActRIIA/B and initiating downstream Smad2/3 phosphorylation
Inhibition of Smad2/3 signaling in skeletal muscle cells removes suppression of myogenesis and protein synthesis, leading to increased muscle fiber size and total lean mass
Inhibition of Smad2/3 signaling in adipocytes reduces expression of adipogenic transcription factors, suppresses lipid storage, and promotes lipolysis, resulting in decreased fat mass and reduced ectopic fat in liver and muscle
Evidence from Studies
Supporting (1)
Community contributions welcome
370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms
This drug, bimagrumab, helped people with obesity and diabetes lose fat and gain muscle without making them eat less — meaning it directly changed how their bodies stored fat and built muscle, like a targeted reset button for body composition.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Bimagrumab Trials on Body Composition in Obesity and Type 2 Diabetes
Systematic review and meta-analysis of all randomized controlled trials in adults with obesity and type 2 diabetes comparing weekly intravenous bimagrumab at 10 mg/kg for 48 weeks versus placebo, measuring changes in total body fat mass and lean mass while controlling for caloric intake.
Double-Blind Placebo-Controlled Trial of Bimagrumab on Body Composition in Obesity and Type 2 Diabetes
Double-blind, placebo-controlled trial in adults with obesity and type 2 diabetes (n≥200), receiving weekly intravenous bimagrumab at 10 mg/kg or placebo for 48 weeks, with strict dietary monitoring to ensure no change in caloric intake, measuring primary outcomes as change in total body fat mass and lean mass via DEXA.
Prospective Cohort Study of Bimagrumab Use and Body Composition Changes in Real-World Obesity and Type 2 Diabetes Population
Prospective cohort study following adults with obesity and type 2 diabetes who receive bimagrumab at 10 mg/kg weekly for 48 weeks versus those who do not, with serial measurements of body composition and documented daily caloric intake over 48 weeks.
In Vitro Analysis of Bimagrumab's Effect on Human Adipocyte and Myocyte Differentiation and Metabolism
In vitro exposure of human adipocytes and myocytes to bimagrumab at 10 mg/kg equivalent concentrations, measuring changes in lipid accumulation, protein synthesis, and metabolic markers over 48 hours, with and without caloric restriction mimetics.
Animal Model Study of Bimagrumab on Body Composition in Diet-Induced Obesity and Diabetic Mice
Study in C57BL/6 mice with diet-induced obesity and type 2 diabetes, receiving weekly intravenous bimagrumab at 10 mg/kg equivalent dose for 48 weeks, with controlled caloric intake, measuring fat mass and lean mass via MRI and tissue analysis.